Compare Heron Therapeutics Inc (HRTX) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nano Dimension Ltd - ADR — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Nano Dimension Ltd - ADR is far larger — about 4.8× Heron Therapeutics Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| HRTX | NNDM | |
|---|---|---|
Market Cap | $68.01M | $328.52M |
Volume | 1,891,941 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $1.49 | $2.14 |
52-Week Low | $0.27 | $1.21 |
Typical Hold Time | 35 Days | 43 Days |
Enterprise Value | $174.75M | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
NNDM trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains deeply unprofitable with a -135.18% net margin. Recent strategic moves include cost-cutting initiatives and board changes to improve capital allocation. Cash burn remains a concern despite $757M in cash reserves.
The outlook remains challenging due to persistent losses and negative cash flow. Investment opportunity exists if restructuring succeeds in achieving profitability. Key risks include execution on cost savings, competitive pressures in additive manufacturing, and reliance on strategic asset sales to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
